Company intelligence / Profile preview
APEIRON Biologics AG
Vienna, —, Austriaapeiron-biologics.com ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Commercial
01
Overview
APEIRON developed Qarziba® (dinutuximab beta), a monoclonal antibody approved in the EU since May 2017 for high-risk neuroblastoma. The product was outlicensed to EUSA Pharma and is now marketed by Recordati S.p.A. globally except China. The company also advanced APN01, an ACE2-based enzyme therapeutic, into Phase II trials for COVID‑19 and ARDS with positive clinical signals reported. Its autologous cell therapy program APN401 targets the immune checkpoint Cbl-b using RNAi technology and has entered early clinical trials in solid tumors[1][4][6][8].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (e.g., dinutuximab beta)Enzyme therapeutics (e.g., alunacedase alfa/APN01)Autologous cell therapy (RNAi-based; e.g., APN401)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
EUSA Pharma Ltd./Recordati S.p.A.: global commercialization of Qarziba® outside China.BeiGene Ltd.: commercialization rights within mainland China.MaxCyte Inc.: licensing agreement to use ExPERT™ electroporation platform for manufacturing cell therapies like APN401.[5]
Beyond the preview
Go deeper on APEIRON Biologics AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APEIRON Biologics AG.